Abercrombie george b - direct investment history in Inspire pharmaceuticals inc

Filed on 2011-05-16 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-11-030108.txt Sec File: edgar/data/1485939/0001181431-11-030108-index.htm

2011-05-13 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc sold 12739 shares remaining shares owned 0

Restricted Stock Unit Inspire Pharmaceuticals Inc Isph underlying security shares 12739 underlying security title Common Stock

f2 pursuant to the merger agreement, these restricted stock units ("rsus"), whether or not vested, were fully vested immediately prior to and cancelled immediately following the acceptance time under the merger agreement in exchange for the right to receive cash payment for each such rsu of $5.00, net to the seller in cash, without interest and less any required withholding taxes.


Filed on 2011-05-16 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-11-030108.txt Sec File: edgar/data/1485939/0001181431-11-030108-index.htm

2011-05-13 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc sold 6873 shares remaining shares owned 0

Restricted Stock Unit Inspire Pharmaceuticals Inc Isph underlying security shares 6873 underlying security title Common Stock

f2 pursuant to the merger agreement, these restricted stock units ("rsus"), whether or not vested, were fully vested immediately prior to and cancelled immediately following the acceptance time under the merger agreement in exchange for the right to receive cash payment for each such rsu of $5.00, net to the seller in cash, without interest and less any required withholding taxes.


Filed on 2011-05-16 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-11-030108.txt Sec File: edgar/data/1485939/0001181431-11-030108-index.htm

2011-05-13 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc sold 2371 shares remaining shares owned 0

Stock Option Right To Buy Inspire Pharmaceuticals Inc Isph exercise price 6.28 has valueitem expiration due date 2017-02-28 underlying security shares 2371 underlying security title Common Stock

f1 these stock options were cancelled in accordance with the terms and conditions of the agreement and plan of merger, dated as of april 5, 2011, by and among, merck & co., inc., monarch transaction corp. and inspire pharmaceuticals, inc. (the "merger agreement"). as the exercise price of the options was at or above $5.00, no cash payment was provided.


Filed on 2011-05-16 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-11-030108.txt Sec File: edgar/data/1485939/0001181431-11-030108-index.htm

2011-05-13 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc sold 18970 shares remaining shares owned 0

Stock Option Right To Buy Inspire Pharmaceuticals Inc Isph exercise price 6.28 has valueitem expiration due date 2017-02-28 underlying security shares 18970 underlying security title Common Stock

f1 these stock options were cancelled in accordance with the terms and conditions of the agreement and plan of merger, dated as of april 5, 2011, by and among, merck & co., inc., monarch transaction corp. and inspire pharmaceuticals, inc. (the "merger agreement"). as the exercise price of the options was at or above $5.00, no cash payment was provided.


Filed on 2011-05-16 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-11-030108.txt Sec File: edgar/data/1485939/0001181431-11-030108-index.htm

2011-05-13 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc sold 10164 shares remaining shares owned 0

Stock Option Right To Buy Inspire Pharmaceuticals Inc Isph exercise price 5.82 has valueitem expiration due date 2017-06-02 underlying security shares 10164 underlying security title Common Stock

f1 these stock options were cancelled in accordance with the terms and conditions of the agreement and plan of merger, dated as of april 5, 2011, by and among, merck & co., inc., monarch transaction corp. and inspire pharmaceuticals, inc. (the "merger agreement"). as the exercise price of the options was at or above $5.00, no cash payment was provided.


Filed on 2011-05-16 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-11-030108.txt Sec File: edgar/data/1485939/0001181431-11-030108-index.htm

2011-05-13 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc sold 1099 shares at $5.00 remaining shares owned 0

Common Stock Inspire Pharmaceuticals Inc Isph Transaction code: U Disposition due to a tender of shares in a change of control transaction


Filed on 2010-06-07 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-031724.txt Sec File: edgar/data/1485939/0001181431-10-031724-index.htm

2010-06-03 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc sold 1592 shares at $0 remaining shares owned 0

Restricted Stock Units Inspire Pharmaceuticals Inc Isph exercise date 2010-06-03 underlying security shares 1592 underlying security title Common Stock

f5 each restricted stock unit represents a contingent right to receive one share of the common stock of inspire pharmaceuticals, inc. the shares will be delivered following the end of the scheduled vesting date or 60 days following an earlier vesting date that occurs as a result of the grantee's separation from service.


Filed on 2010-06-07 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-031724.txt Sec File: edgar/data/1485939/0001181431-10-031724-index.htm

2010-06-03 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 6873 shares at $0 remaining shares owned 6873

Restricted Stock Units Inspire Pharmaceuticals Inc Isph underlying security shares 6873 underlying security title Common Stock

f5 each restricted stock unit represents a contingent right to receive one share of the common stock of inspire pharmaceuticals, inc. the shares will be delivered following the end of the scheduled vesting date or 60 days following an earlier vesting date that occurs as a result of the grantee's separation from service.
f6 shall vest on june 1, 2011 or the date of the annual meeting of stockholders of such year, if earlier.


Filed on 2010-06-07 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-031724.txt Sec File: edgar/data/1485939/0001181431-10-031724-index.htm

2010-06-03 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 10164 shares at $0 remaining shares owned 10164

Stock Option Right To Buy Inspire Pharmaceuticals Inc Isph exercise price 5.82 has valueitem expiration due date 2017-06-02 underlying security shares 10164 underlying security title Common Stock

f4 shall vest over the one year period commencing on the date of the grant (twenty-five percent (25%) of the total shares per quarter).


Filed on 2010-06-07 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-031724.txt Sec File: edgar/data/1485939/0001181431-10-031724-index.htm

2010-06-03 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc sold 493 shares at $5.82 remaining shares owned 1099

Common Stock Inspire Pharmaceuticals Inc Isph Transaction code: F Payment of exercise price or tax liability by delivering or withholding securities

f2 the shares represent the payment of withholding tax liability incident to the vesting of restricted stock units granted march 1, 2010.
f3 represents the number of shares received upon the vesting of restricted stock units granted march 1, 2010 following the payment of withholding tax liability.


Filed on 2010-06-07 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-031724.txt Sec File: edgar/data/1485939/0001181431-10-031724-index.htm

2010-06-03 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 1592 shares at $0 remaining shares owned 1592

Common Stock Inspire Pharmaceuticals Inc Isph Transaction code: M Exercise or conversion of derivative security

f1 shares received on june 3, 2010 upon vesting of restricted stock units granted on march 1, 2010. see footnotes 2 and 3 below.


Filed on 2010-03-02 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-013128.txt Sec File: edgar/data/1485939/0001181431-10-013128-index.htm

2010-03-01 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 1592 shares at $0 remaining shares owned 1592

Restricted Stock Units Inspire Pharmaceuticals Inc Isph underlying security shares 1592 underlying security title Common Stock

f5 each restricted stock unit represents a contingent right to receive one share of the common stock of inspire pharmaceuticals, inc. the shares will be delivered following the end of the scheduled vesting date or 60 days following an earlier vesting date that occurs as a result of the grantee's separation from service.
f4 restricted stock units shall vest on the date of the 2010 annual meeting of stockholders.


Filed on 2010-03-02 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-013128.txt Sec File: edgar/data/1485939/0001181431-10-013128-index.htm

2010-03-01 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 12739 shares at $0 remaining shares owned 12739

Restricted Stock Units Inspire Pharmaceuticals Inc Isph underlying security shares 12739 underlying security title Common Stock

f5 each restricted stock unit represents a contingent right to receive one share of the common stock of inspire pharmaceuticals, inc. the shares will be delivered following the end of the scheduled vesting date or 60 days following an earlier vesting date that occurs as a result of the grantee's separation from service.
f3 restricted stock units shall vest as follows: 40% of such units on june 1, 2011; 30% of such units on june 1, 2012; and 30% of such units on june 1, 2013 (or the date of the 2013 annual meeting of stockholders, if earlier).


Filed on 2010-03-02 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-013128.txt Sec File: edgar/data/1485939/0001181431-10-013128-index.htm

2010-03-01 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 2371 shares at $0 remaining shares owned 2371

Stock Option Right To Buy Inspire Pharmaceuticals Inc Isph exercise price 6.28 has valueitem expiration due date 2017-02-28 underlying security shares 2371 underlying security title Common Stock

f2 stock option shall vest on the date of the 2010 annual meeting of stockholders.


Filed on 2010-03-02 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-013128.txt Sec File: edgar/data/1485939/0001181431-10-013128-index.htm

2010-03-01 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 18970 shares at $0 remaining shares owned 18970

Stock Option Right To Buy Inspire Pharmaceuticals Inc Isph exercise price 6.28 has valueitem expiration due date 2017-02-28 underlying security shares 18970 underlying security title Common Stock

f1 stock option will vest quarterly over three years commencing on the date of grant as follows: 40% of such shares in year one, 30% of such shares in year two, and 30% of such shares in year three.


Filed on 2010-03-02 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-013127.txt Sec File: edgar/data/1485939/0001181431-10-013127-index.htm

2010-03-01 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 1592 shares at $0 remaining shares owned 1592

Restricted Stock Units Inspire Pharmaceuticals Inc Isph underlying security shares 1592 underlying security title Common Stock

f5 each restricted stock unit represents a contingent right to receive one share of the common stock of inspire pharmaceuticals, inc. the shares will be delivered following the end of the scheduled vesting date or 60 days following an earlier vesting date that occurs as a result of the grantee's separation from service.
f4 restricted stock units shall vest on the date of the 2010 annual meeting of stockholders.


Filed on 2010-03-02 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-013127.txt Sec File: edgar/data/1485939/0001181431-10-013127-index.htm

2010-03-01 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 12739 shares at $0 remaining shares owned 12739

Restricted Stock Units Inspire Pharmaceuticals Inc Isph underlying security shares 12739 underlying security title Common Stock

f5 each restricted stock unit represents a contingent right to receive one share of the common stock of inspire pharmaceuticals, inc. the shares will be delivered following the end of the scheduled vesting date or 60 days following an earlier vesting date that occurs as a result of the grantee's separation from service.
f3 restricted stock units shall vest as follows: 40% of such units on june 1, 2011; 30% of such units on june 1, 2012; and 30% of such units on june 1, 2013 (or the date of the 2013 annual meeting of stockholders, if earlier).


Filed on 2010-03-02 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-013127.txt Sec File: edgar/data/1485939/0001181431-10-013127-index.htm

2010-03-01 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 2371 shares at $0 remaining shares owned 2371

Stock Option Right To Buy Inspire Pharmaceuticals Inc Isph exercise price 6.28 has valueitem expiration due date 2017-02-28 underlying security shares 2371 underlying security title Common Stock

f2 stock option shall vest on the date of the 2010 annual meeting of stockholders.


Filed on 2010-03-02 by Abercrombie George B SEC CIK 1485939 Form 4

Accession 0001181431-10-013127.txt Sec File: edgar/data/1485939/0001181431-10-013127-index.htm

2010-03-01 Abercrombie George B (CIK 1485939) through Direct

Invested in Inspire Pharmaceuticals Inc bought 18970 shares at $0 remaining shares owned 18970

Stock Option Right To Buy Inspire Pharmaceuticals Inc Isph exercise price 6.28 has valueitem expiration due date 2017-02-28 underlying security shares 18970 underlying security title Common Stock

f1 stock option will vest quarterly over three years commencing on the date of grant as follows: 40% of such shares in year one, 30% of such shares in year two, and 30% of such shares in year three.